Kevin Brewer
Analyst · Patrick Ho with Stifel Nicolaus. Your line is open. Please go ahead
Thank you, Mary. We are pleased with our Q1 financial performance and guidance for Q2. Revenue in Q1 was above company guidance and analyst consensus, driven by the continued ramp of Purion H. Gross margin was slightly ahead of our improvement plans, fueled by lower material and labor costs and a broad product mix, and quarter end cash was $74.5 million, which includes positive cash flow from operations, in addition to proceeds from the sale of our headquarters. Current cash is at the highest level net of debt since 2002. Looking at our first quarter results, revenue finished at $73.3 million, up 17.2% from $62.5 million in Q4 and above our guidance. System sales were $42.5 million, up 42.3% from $29.9 million in Q4. GSS revenue finished at $30.8 million, down 5% from $32.7 million in Q4. Q1 sales to our top 10 customers accounted for about 81% of our total sales, compared to 70% in Q4, with one of these customers at 10% or above. Q1 system bookings were $65.9 million, compared to $56.1 million in Q4, with a Q1 book-to-bill ratio of 1.46 versus 1.72 in Q4. Backlog in the quarter finished at $60.1 million, compared to $37.9 million in Q4. Q1 combined SG&A and R&D spending was $19.9 million, compared to our guidance $19 million. Higher costs were mainly due to unplanned proxy fees and incremental R&D spending to support the rapid ramp of Purion H. SG&A in the quarter was $11.7 million, with R&D at $8.2 million. In Q2, we expect SG&A and R&D spending to return to our model of approximately $18 million. Gross margin in Q1 finished at 31.9% and above guidance compared to 30.1% in Q4. Lower than planned material and labor costs in our Purion products and higher overall factory efficiency drove this improvement. In Q1, we also took our final charges for capitalized variances that were accrued during the 2014 pause. Gross margin improvement remains a top focus across the business, and I’m personally involved in critical programs that drive lower product cost. As highlighted in our last call, gross margin improvement roadmaps take advantage of Kaizens that optimize factory and supply chain efficiency, Purion platform commonality that provides supply chain leverage through higher part volume, launching ship-from-cell on all Purion products to shorten manufacture and cycle time and improve labor productivity, and implementation of factory and supplier Kanban programs to improve inventory turns in our cash-to-cash cycle. Operating profit in Q1 was $3.4 million, above our guidance and compares to $0.4 million in Q4. Q1 net income of $1.9 million, or $0.02 per share was at the high end of our guidance compared to $0.2 million, or $0.00 per share in Q4. Q1 inventory ended at $109.5 million compared to $$104.1 million in Q4. The increase in inventory was primarily driven by field stock to support the increasing number of Purion shipments. However, inventory turns did increase in the quarter, driven by improving factory cycle times. Q1 accounts payable were $30.5 million compared to $21.6 million in Q4, due to higher manufacturing volume and the timing of material purchases. Q1 receivables finished at $42.8 million flat with Q4. Q1 cash and cash equivalents finished at $74.5 million with no debt and well above our guidance of mid-60s, driven by proceeds from the sale of our headquarters and cash generated from operations. This compares to a cash balance of $30.8 million in Q4. We expect Q4 cash flow to remain positive and to increase cash to approximately $80 million. In summary, I would like to direct you to the business model in our investor presentation, as a way to look at Axcelis financially. The model shows our target quarterly revenues for 2015 are in the $70 million to $75 million range with gross margins in the mid-30% range. Combined SG&A and R&D spending should be modeled at approximately $18 million. This model results in quarterly net income of approximately $5 million to $7 million. Based on our Q2 guidance, we are approaching this model. Looking forward, the longer-term model highlights the amount of leverage in the business. Axcelis will generate significant profits in cash as gross margins move towards 40% and beyond. Implementation of the programs I discussed will fuel a steady improvement of gross margin while the success of Purion will drive the revenue growth. With that, I will now turn the call over to Doug, who will discuss current market conditions and opportunities for Axcelis. Doug?